IXICO (PHYOF) EBIT: $-4.20 Mil (TTM As of Mar. 2026)


PHYOF IXICO PLC PHYOF
42 GF Score
Price $0.07
GF Value $0.07
! 2 Warning Signs
View Full Analysis

What is IXICO EBIT?

IXICO PHYOF -53.33% 42 EBIT is $-4.20 Mil as of Mar. 2026. GuruFocus rates PHYOF with a GF Score™ of 42/100 and a GF Value™ of $0.07. The stock has 2 warning signs investors should review.

IXICO's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was $-2.10 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.20 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. IXICO's annualized ROC % for the quarter that ended in Mar. 2026 was -17.66%. IXICO's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -221.45%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. IXICO's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -18.30%.

IXICO  (OTCPK:PHYOF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

IXICO's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-3.31 * ( 1 - 29.24% )/( (13.695 + 12.825)/ 2 )
=-2.342156/13.26
=-17.66 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=18.701 - 0.226 - ( 4.78 - max(0, 2.78 - 8.424+4.78))
=13.695

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=17.315 - 2.257 - ( 2.233 - max(0, 2.404 - 6.809+2.233))
=12.825

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

IXICO's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-4.202/( ( (0.226 + max(0.471, 0)) + (0.779 + max(2.319, 0)) )/ 2 )
=-4.202/( ( 0.697 + 3.098 )/ 2 )
=-4.202/1.8975
=-221.45 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.968 + 0 + 1.082) - (0.226 + 0 + 2.353)
=0.471

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.889 + 0 + 1.687) - (2.257 + 0 + 0)
=2.319

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

IXICO's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-4.197/22.929
=-18.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IXICO EBIT Related Terms

IXICO EBIT Historical Data

* Premium members only.

The historical data trend for IXICO's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IXICO EBIT Chart

IXICO Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.54 1.04 -1.65 -2.74 -3.29

IXICO Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.95 -0.71 -1.14 -2.10 -2.10

PHYOF vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, IXICO's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IXICO EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IXICO's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where IXICO's EV-to-EBIT falls into.


PHYOF
42GF Score
IXICO PLC PHYOF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IXICO EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-4.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-4.20 Mil mean?
IXICO (PHYOF) has a EBIT of $-4.20 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on IXICO.
Is IXICO's EBIT too high?
IXICO's current EBIT is $-4.20 Mil. Overall, IXICO has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does IXICO's EBIT compare to VRTX and REGN?
IXICO's EBIT of $-4.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on IXICO. IXICO's current EBIT is $-4.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IXICO stock overvalued right now?
IXICO (PHYOF) has a current EBIT of $-4.20 Mil. The stock's GF Value™ is $0.07, compared to a current price of $0.07 — trading right at its estimated fair value. The current EBIT is $-4.20 Mil. IXICO's overall GF Score™ is 42/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For IXICO (PHYOF), the current EBIT is $-4.20 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IXICO (PHYOF) Overvalued in 2026?

Based on GuruFocus' analysis, IXICO stock appears to be undervalued. The current stock price of $0.07 is trading 0% below its estimated GF Value™ of $0.07.

Key valuation signals for PHYOF:

  • EBIT: $-4.20 Mil
  • GF Value™: $0.07 vs. price of $0.07 (0% below fair value)
  • GF Score™: 42/100 with 2 warning signs

No single metric tells the full story. See the PHYOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IXICO Business Description

Other Exchanges IXI:UK
Address 15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN
IXICO PLC provides neuroscience imaging and biomarker analytics services, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. It operates as an imaging contract research organization, supporting clinical trials for neurological disorders by processing and analyzing imaging data. Its platform is used to measure biomarkers associated with diseases such as Alzheimer's, Huntington's, and Parkinson's.
42GF Score

Get the complete analysis for PHYOF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.07
Price
$0.07
GF Value